Cybin
Selects
Alcohol Use
Disorder Indication
for
Psychedelic
Molecule
CYB003
TORONTO,
CANADA -- April 26, 2021 -- InvestorsHub NewsWire
-- Cybin
Inc. (NEO:CYBN)
(OTCQB:CLXPF)
("Cybin"
or the "Company"),
a biotechnology company focused on progressing psychedelic
therapeutics, today announced that it has selected
Alcohol Use
Disorder ("AUD") as the initial target
indication
for its
proprietary deuterated psychedelic tryptamine, CYB003.
AUD is a chronic relapsing
brain disorder characterized by an impaired ability to stop or
control alcohol use despite adverse social, occupational, or
health consequences.1
Approximately 5.8 percent or
14.4 million adults in the United States ages 18 and older had AUD
in 2018. This includes 9.2 million men and 5.3 million
women.1
To be diagnosed
with AUD, individuals must meet certain criteria outlined in the
Diagnostic and Statistical Manual of Mental Disorders
("DSM"). Under DSM–5, the
current
version of
the DSM, anyone meeting any two of the 11 criteria during the same
12-month period receives a diagnosis of AUD. The severity of
AUD—mild, moderate, or severe—is based on the number of
criteria met.1
"The
evidence of
increased alcohol use during this ongoing pandemic
is startling. For
so many individuals and families, Alcohol Use Disorder can be
disruptive, even devastating. We are optimistic that CYB003
could have the potential to improve the lives of AUD sufferers and
their loved ones by providing a durable respite from alcohol
dependence and the potential to overcome
this often-crippling
disease," stated Doug Drysdale, Chief
Executive Officer.
Cybin is confident that its proprietary
deuterated CYB003 New Chemical Entity
("NCE") could be an ideal investigational new drug
("IND") candidate for a future AUD clinical trial
once
further
pre-clinical
data
has
been
collected. Cybin is targeting an IND
filing for CYB003 by the end of calendar 2021.
Cybin's intellectual property-driven
strategy focuses on the discovery
of NCEs
derived from parent
molecules with the potential to be
faster
acting and
more commercially viable with an optimized duration of
action,
utilizing proprietary
deuteration processes. As the psychedelic
industry continues
to evolve with positive studies, Cybin believes that these molecules
may
have the potential
to fill current unmet treatment needs for various psychiatric and
neurological conditions.
Alcohol-Related
Emergencies and Deaths in the United States2
-
The rate of all
alcohol-related ED visits increased 47 percent between 2006 and
2014.
-
Alcohol
contributes to about 18.5 percent of ED visits and 22.1 percent of
overdose deaths.
-
An
estimated 95,000 people in the U.S. (approximately 68,000 men and
27,000 women) die from alcohol-related causes annually,
making alcohol the
third-leading preventable cause of death in the United
States.
-
Between
2011 and 2015, the leading causes of alcohol-attributable deaths
due to chronic conditions in the United States included alcohol-associated liver
disease, heart disease and stroke, liver cirrhosis, digestive tract
cancers, liver cancer, breast cancer, and hypertension.
-
In
2015, alcohol-impaired driving fatalities accounted for
29.0 percent of all
driving fatalities.
-
In
2010, alcohol misuse cost the United States $249 billion.
Three-quarters of
the total cost of alcohol misuse is related to binge
drinking.
Global
Burden2
-
In 2016, 3 million
deaths, or 5.3 percent of all global deaths were attributable to
alcohol consumption.
-
Globally,
alcohol misuse was the seventh-leading risk factor for premature
death and disability in 2016.
-
According
to a 2014 World Health Organization ("WHO") report, alcohol misuse was the first-leading
risk factor
for premature death and disability, among people ages 15 to
49.
-
In
2016, 5.3 percent of the burden of disease and injury worldwide
(134 million disability-adjusted life-years
["DALYs"]) was attributable to alcohol
consumption.
-
In
2018, WHO reported that alcohol contributed to more than 200
diseases and injury-related health conditions, ranging from liver
diseases, road injuries, and violence, to cancers, cardiovascular diseases,
suicides, tuberculosis, and HIV/AIDS.
1
https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-use-disorder
2
https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics
About
Cybin
Cybin is a leading
biotechnology company focused on progressing psychedelic
therapeutics by utilizing proprietary drug discovery platforms,
innovative drug delivery systems, novel formulation approaches and
treatment regimens for psychiatric disorders.
Cautionary
Notes and Forward-Looking Statements
Certain statements
in this news release related to the Company are forward-looking
statements and are prospective in nature. Forward-looking
statements are not based on historical facts, but rather on current
expectations and projections about future events and are therefore
subject to risks and uncertainties which could cause actual results
to differ materially from the future results expressed or implied
by the forward-looking statements. These statements generally can
be identified by the use of forward-looking words such as "may",
"should", "could", "intend", "estimate", "plan", "anticipate",
"expect", "believe" or "continue", or the negative thereof or
similar variations. Forward-looking statements in this news
release may include statements regarding
enhanced liquidity, the value of additional capital markets
exposure, access to institutional and retail investors, the
Company's new strategic brand messaging campaign, and psychedelic
drug development programs to potentially treat mental health
disorders.
There are numerous risks and uncertainties that could cause actual
results and Cybin's plans and objectives to differ materially from
those expressed in the forward-looking information. Actual results
and future events could differ materially from those anticipated in
such information. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend to update these forward-looking
statements.
Cybin makes no
medical, treatment or health benefit claims about Cybin's proposed
products. The U.S. Food and Drug Administration, Health Canada or
other similar regulatory authorities have not evaluated claims
regarding psilocybin, psychedelic tryptamine, tryptamine
derivatives or other psychedelic compounds or nutraceutical
products. The efficacy of such products has not been confirmed by approved
research. There is no assurance that the use of psilocybin,
psychedelic tryptamine, tryptamine derivatives or other psychedelic
compounds or nutraceuticals can diagnose, treat, cure or prevent
any disease or condition. Vigorous scientific research and clinical
trials are needed. Cybin has not conducted clinical trials for the
use of its proposed products. Any references to quality,
consistency, efficacy and safety of potential products do not imply
that Cybin verified such in clinical trials or that Cybin will
complete such trials. If Cybin cannot obtain the approvals or
research necessary to commercialize its business, it may have a
material adverse effect on Cybin's performance and
operations.
The NEO
Exchange has neither approved nor disapproved the contents of this
news release and is not responsible for the adequacy and accuracy
of the contents herein.
Investor
Contacts:
Tim Regan/Scott
Eckstein
KCSA Strategic
Communications
Cybin@kcsa.com
Lisa M.
Wilson
In-Site
Communications, Inc.
lwilson@insitecony.com
Media
Contacts:
John
Kanakis
Cybin
Inc.
John@cybin.com
Annie
Graf
KCSA Strategic
Communications
agraf@kcsa.com
Faith
Pomeroy-Ward
In-Site
Communications, Inc.
Faith@insitecony.com